Bone Marrow Transplant Induction and Conditioning in One
Iomab-B, Actinium’s lead asset, is in a pivotal Phase 3 clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory Acute Myeloid Leukemia (AML) prior to receiving a bone marrow transplant (BMT), also known as a hematopoietic stem cell transplant or HSCT. View highlights of Key Opinion Leaders discussing Iomab-B:
Actinium Pharmaceuticals' drug development pipeline features Iomab-B, which is in a pivotal Phase 3 clinical trial, Actimab-A, which is in a Phase 2 clinical trial, and Actimab-M currently in a Phase 1 clinical trial. Actinium is focused on continuing to expand its drug development pipeline by leveraging its alpha-particle technology platform and domain expertise.
